Two recent drug approvals changed the game for ocular surface disease: Xdemvy (lotilaner ophthalmic solution) 0.25 percent (Tarsus Pharmaceuticals) for Demodex blepharitis, and Miebo (perfluorohexyloctane ophthalmic solution) from Bausch + Lomb and Novali

Yari Mitchell spent nearly 13 years with AcuFocus, an ophthalmic device company, before overseeing its acquisition by Bausch + Lomb. As head of Y Factor Consulting, she now helps innovators move their product from the lab to a funded company.Greg Kunst, P

Wesley Jackson, PhD, spent years conducting post-doctoral research and writing grants, all the while setting the wheels in motion to launch Valitor.Valitor is developing VLTR-557 a long-lasting anti-VEGF. The technology platform, a multivalent polymer (MV

Aziz Mottiwala, Chief Commercial Officer of Tarsus Pharmaceuticals, says the company looks for honest unmet needs when deciding what targets to explore. It also looks for opportunities to be the first or the best.The company may meet both objectives with

Daniela Ferrara, Principal Medical Director at Genentech, calls her extensive medical training in Brazil her north star. Yet, she was frustrated by the limitations of clinical practice.Having patients go blind under my watch, I realized I would never

Host Carey Powers caught up with two digital health experts right after the Digital Ophthalmic Society (DOS) Digital Day program at the recent ASCRS conference in San Diego, California: Ranya Habash, MD, cofounder of MetaMed, DOS board member, and CEO of

Innovation happens in labs, workshops, and garages worldwide. How does it happen in a global enterprise like Johnson & Johnson?Christoph Vonwiller, President of the Asia Pacific Region for Johnson & Johnson Vision, sheds light on that topic during

Brian Culley, CEO of Lineage Cell Therapeutics, describes his companys approach as replace and restore.In certain settings, replacing whole cells may provide restorative benefits that go beyond small molecule drugs, or even anti-VEGF therapies.Replacin

For todays episode, the newest addition to the OIS Podcast team, Carey Powers, sits down with the newest additions to the Staar Surgical team: Warren Foust, Chief Operating Officer; and Magda Michna, PhD, Chief Clinical, Regulatory, and Medical Affairs O

Nataa Jovic has led marketing strategies for retina products since the launch of Visudyne. Approved by the FDA in 2002, Visudyne was the first commercially available therapy to treat wet AMD.Today, Jovic applies her scientific background and retina expe